Carron Shmerling Lisa Net Worth

The estimated Net Worth of Carron Shmerling Lisa is at least 590 千$ dollars as of 8 February 2007. Carron Lisa owns over 11,250 units of Momenta Pharmaceuticals stock worth over 590,400$ and over the last 18 years Carron sold MNTA stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Carron Lisa MNTA stock SEC Form 4 insiders trading

Carron has made over 1 trades of the Momenta Pharmaceuticals stock since 2007, according to the Form 4 filled with the SEC. Most recently Carron exercised 11,250 units of MNTA stock worth 94,613$ on 8 February 2007.

The largest trade Carron's ever made was exercising 11,250 units of Momenta Pharmaceuticals stock on 8 February 2007 worth over 94,613$. On average, Carron trades about 5,625 units every 0 days since 2007. As of 8 February 2007 Carron still owns at least 11,250 units of Momenta Pharmaceuticals stock.

You can see the complete history of Carron Lisa stock trades at the bottom of the page.

What's Carron Lisa's mailing address?

Carron's mailing address filed with the SEC is C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE, MA, 02142.

Insiders trading at Momenta Pharmaceuticals

Over the last 20 years, insiders at Momenta Pharmaceuticals have traded over 110,027,424$ worth of Momenta Pharmaceuticals stock and bought 827,300 units worth 5,505,611$ . The most active insiders traders include Christoph H Westphal、Craig A Wheeler、Peter Barrett. On average, Momenta Pharmaceuticals executives and independent directors trade stock every 6 days with the average trade being worth of 448,442$. The most recent stock trade was executed by Ian Fier on 20 August 2020, trading 1,808 units of MNTA stock currently worth 94,323$.

What does Momenta Pharmaceuticals do?

Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.

Complete history of Carron Lisa stock trades at Momenta Pharmaceuticals

Momenta Pharmaceuticals executives and stock owners

Momenta Pharmaceuticals executives and other stock owners filed with the SEC include:

• Donna Roy Grogan,
  Director
• Jose Carlos Gutierrez Ramos,
  Director
• Santiago Arroyo,
  SVP, Chief Medical Officer
• Craig A Wheeler,
  President & CEO
• Corey N. Fishman,
  Director
• Marsha Fanucci,
  Director
• James R Sulat,
  Director
• Bruce Leicher,
  SVP & General Counsel
• Matthew P. Ottmer,
  Chief Operating Officer
• Richard P Shea,
  VP, Chief Financial Officer
• Georges Gemayel,
  Director
• Thomas P Koestler,
  Director
• Steven C Gilman,
  Director
• Bruce Downey,
  Director
• Elizabeth Stoner,
  Director
• Scott M Storer,
  SVP, CFO
• James M. Roach,
  Senior VP, Development and Chi
• Michelle Robertson,
  Chief Financial Officer
• Anthony M. Manning,
  Chief Scientific Officer
• Jo Ann Beltramello,
  Chief HR and Inf. Officer
• Alejandra Carvajal,
  Chief Legal Officer
• Ian Fier,
  Chief Mfg and Program Officer
• Young Kwon,
  Chief Financial & Bus. Officer
• Peter Barrett,
  Director
• Peter Barton Hutt,
  Director
• Paul D Goldenheim,
  Director
• Stephen B Brugger,
  VP, Strategic Prod Devl.
• John L Zabriskie,
  Director
• Ram Sasisekharan,
  Director
• Venture Management Co Iii L...,
  
• Christoph H Westphal,
  Director
• Venture Fund V Lpatlas Vent...,
  
• Bennett M Shapiro,
  Director
• Stephen T Reeders,
  Director
• International Life Sciences...,
  10% owner
• Ganesh Venkataraman,
  VP, Technology
• Venture Fund V Lpatlas Vent...,
  
• Venture Management Co Iii L...,
  
• Michael Franken,
  President, Biosimilars Busines
• Robert Langer,
  Director
• Carron Shmerling Lisa,
  V.P., Legal Affairs
• John E Bishop,
  VP Pharma Sciences & Manufact
• Susan K Whoriskey,
  VP, Licensing and Bus. Develop
• Alan L Crane,
  President and CEO
• Venture Fund V Lpatlas Vent...,
  
• John K Clarke,
  Director
• Jane F Barlow,
  Director
• Agnieszka Cieplinska,
  Chief Accounting Officer (PAO)